ArticleJournal of clinical microbiology1999
Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species.
Article in Journal of clinical microbiology, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 151 citations in OpenAlex.
- The Dual PathogenJournal of fungi (Basel, Switzerland) · 2025Review
- Intracameral voriconazole for severe fungal keratitis: a case series.Arquivos brasileiros de oftalmologia · 2025Article
- Natamycin Ocular Delivery: Challenges and Advancements in Ocular Therapeutics.Advances in therapy · 2023Review
- Therapeutic Drug Monitoring of Antifungal Agents in Critically Ill Patients: Is There a Need for Dose Optimisation?Antibiotics (Basel, Switzerland) · 2022Review
- Sixty years of Amphotericin B: An Overview of the Main Antifungal Agent Used to Treat Invasive Fungal Infections.Infectious diseases and therapy · 2021Review
- Amphotericin B and Other Polyenes-Discovery, Clinical Use, Mode of Action and Drug Resistance.Journal of fungi (Basel, Switzerland) · 2020Review
- Fungal Keratitis: Epidemiology, Rapid Detection, and Antifungal Susceptibilities ofBioMed research international · 2019Article
- Airborne transmission of invasive fusariosis in patients with hematologic malignancies.PloS one · 2018Article
- David and Goliath: chemical perturbation of eukaryotes by bacteria.Journal of industrial microbiology & biotechnology · 2016Review
- International Evaluation of MIC Distributions and Epidemiological Cutoff Value (ECV) Definitions for Fusarium Species Identified by Molecular Methods for the CLSI Broth Microdilution Method.Antimicrobial agents and chemotherapy · 2016Article
- Pharmacokinetics and safety of intravitreal caspofungin.Antimicrobial agents and chemotherapy · 2014Article
- European Confederation of Medical Mycology (ECMM) epidemiological survey on invasive infections due to Fusarium species in Europe.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2014Article
- Article
- Disseminated amphotericin-resistant fusariosis in acute leukemia patients: report of two cases.Mycopathologia · 2013Article
- Amphotericin B and voriconazole susceptibility profiles for the Fusarium solani species complex: comparison between the E-test and CLSI M38-A2 microdilution methodology.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2012Article
- Transcriptomic and proteomic profile of Aspergillus fumigatus on exposure to artemisinin.Mycopathologia · 2011Article
- Internet-accessible DNA sequence database for identifying fusaria from human and animal infections.Journal of clinical microbiology · 2010Article
- Proteomic and transcriptomic analysis of Aspergillus fumigatus on exposure to amphotericin B.Antimicrobial agents and chemotherapy · 2008Article
- Molecular phylogenetic diversity, multilocus haplotype nomenclature, and in vitro antifungal resistance within the Fusarium solani species complex.Journal of clinical microbiology · 2008Article
- Species distribution and in vitro antifungal susceptibility patterns of 75 clinical isolates of Fusarium spp. from northern Italy.Antimicrobial agents and chemotherapy · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We compared the activities of amphotericin B, itraconazole, and voriconazole against clinical Aspergillus (n = 82) and Fusarium (n = 22) isolates by a microdilution method adopted from the National Committee for Clinical Laboratory Standards (NCCLS-M27A). RPMI 1640 (RPMI), RPMI 1640 supplemented to 2% glucose (RPMI-2), and antibiotic medium 3 supplemented to 2% glucose (AM3) were used as test media. MICs were determined after 24, 48, and 72 h. A narrow range of amphotericin B MICs was observed for Aspergillus isolates, with minor variations among species. MICs for Fusarium isolates were higher than those for Aspergillus isolates. MICs of itraconazole were prominently high for two previously defined itraconazole-resistant Aspergillus fumigatus isolates and Fusarium solani. Voriconazole showed good in vitro activity against itraconazole-resistant isolates, but the MICs of voriconazole for F. solani were high. RPMI was the most efficient medium for detection of itraconazole-resistant isolates, followed by RPMI-2. While the significance remains unclear, AM3 lowered the MICs, particularly those of amphotericin B.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.